Current perspectives on statins

David J. Maron, Sergio Fazio, MacRae F. Linton

    Research output: Contribution to journalArticlepeer-review

    1082 Scopus citations


    Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride levels in hypertriglyceridemic patients. Statins are well tolerated and have an excellent safety record. Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the relative risk of major coronary events by ≃30% and produce a greater absolute benefit in patients with higher baseline risk. Proposed mechanisms include favorable effects on plasma lipoproteins, endothelial function, plaque architecture and stability, thrombosis, and inflammation. Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents.

    Original languageEnglish (US)
    Pages (from-to)207-213
    Number of pages7
    Issue number2
    StatePublished - Jan 18 2000


    • Atherosclerosis
    • Coronary disease
    • Hypercholesterolemia
    • Statins
    • Trials

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Physiology (medical)


    Dive into the research topics of 'Current perspectives on statins'. Together they form a unique fingerprint.

    Cite this